- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01557335
A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540
A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PA32540 is proposed for the secondary prevention of cardio- and cerebrovascular events in patients at risk for developing aspirin-associated gastric ulcers.
Aspirin 81 mg taken concomitantly with clopidogrel 75 mg as maintenance doses is standard of care in some patients with cardiovascular disease. The combination of aspirin and clopidogrel, however, significantly increases the risk for bleeding events. To mitigate upper gastrointestinal bleeding events, these patients would require the use of a proton pump inhibitor. For that reason, the reference arm in this study uses Prilosec® 40 mg as a comparator - the same proton pump inhibitor at the same dose level.
The primary objective is to evaluate adenosine diphosphate (ADP)-induced platelet aggregation following administration of clopidogrel, EC aspirin 81 mg and EC omeprazole 40 mg, all dosed concomitantly, and PA32540 and clopidogrel dosed separately
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Sinai Center for Thrombosis Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or non-lactating, non-pregnant female subjects who are 40 years or older at the time of initial dosing
--Physical status within normal limits for age and consistent with observations at Screening
- Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed
Exclusion Criteria:
- History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors (PPIs)
- History of hypersensitivity, allergy or intolerance to aspirin or any NSAID and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps
- History of hypersensitivity or intolerance to clopidogrel
- History of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies
- History of malignancy, treated or untreated, within the past five years, with the exception of successfully treated basal cell or squamous cell carcinoma of -Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the Investigator's opinion, would endanger a subject if he/she were to participate in the study
- Presence of an uncontrolled acute, or a chronic medical illness, e.g., GI disorder, diabetes, hypertension, thyroid disorder, bleeding disorder, infection, which in the Investigator's opinion would endanger a subject if he/she were to participate in the study or interfere with the objective of this study
- Schizophrenia or bipolar disorder
- GI disorder or surgery leading to impaired drug absorption
- < 70% platelet aggregation at Screening
- Donation of blood or plasma within 4 weeks of the study
- PPI use or any enzyme inducing/inhibiting agents within 4 weeks prior to dosing
- Taking any antiplatelet drug within 2 weeks of the screening visit or during the study, or more than two 325 mg doses of aspirin or more than 2 doses of any other NSAIDs within 14 days prior to the screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clopidogrel (Plavix®) and PA32540
PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
|
one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
|
Active Comparator: EC aspirin, EC omeprazole, Clopidogrel
|
One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate adenosine diphosphate (ADP)-induced platelet aggregation
Time Frame: 7 days
|
To evaluate adenosine diphosphate (ADP)-induced platelet aggregation following administration of clopidogrel, EC aspirin 81 mg and EC omeprazole 40 mg, all dosed concomitantly, and PA32540 and clopidogrel dosed separately. The endpoint measure is IPA (Individual Platelet Aggregation)at day 7 and PA0 is the platelet aggregation at baseline. The IPA will be analyzed using analyses of variance (ANOVA). |
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate arachidonic acid (AA)-induced platelet aggregation
Time Frame: 7 days
|
To evaluate arachidonic acid (AA)-induced platelet aggregation following administration of clopidogrel, EC aspirin 81 mg and EC omeprazole 40 mg, all dosed concomitantly, and PA32540 and clopidogrel dosed separately. The secondary endpoint is the IPA (Individual Platelet Aggregation) and will be analyzed using the same methodology as the primary endpoint. |
7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Lisa Zimmerman, Pozen
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Aspirin
- Clopidogrel
- Omeprazole
Other Study ID Numbers
- PA32540-111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Platelet Aggregation
-
Vanderbilt UniversityWithdrawnPlatelet AggregationUnited States
-
Texas Tech University Health Sciences CenterCompletedPlatelet AggregationUnited States
-
Edward R. Teitel, M.D.Completed
-
Ruhr University of BochumPfizerCompleted
-
Medisch Spectrum TwenteCompletedPlatelet Aggregation | Blood TransfusionNetherlands
-
AstraZenecaCompletedInhibition on Platelet AggregationUnited States
-
Ospedale Santa Croce-Carle CuneoUnknownPlatelet Aggregation Inhibitors
-
University of California, DavisCompletedVascular Function; Platelet AggregationUnited States
-
Aggredyne, Inc.Completed
-
Vanderbilt UniversityTerminatedPlatelet AggregationUnited States
Clinical Trials on Plavix® and PA32540
-
Khon Kaen UniversityCompletedPharmacodynamicsThailand
-
Applied Science & Performance InstituteCompletedIron Deficiency (Without Anemia)United States
-
POZENCompletedAspirin-Associated Gastric UlcersUnited States
-
Avera McKennan Hospital & University Health CenterAvera Heart Hospital of South Dakota; North Central Heart InstituteCompletedPharmacogenomics and Cardiovascular EventsUnited States
-
POZENCompleted
-
Gangnam Severance HospitalYonsei University; Myung In Pharmaceutical CompanyCompletedCerebral InfarctionKorea, Republic of
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompleted
-
Center for Bioequivalence Studies and Clinical...Ferozsons Laboratories Ltd.Completed
-
Ajou University School of MedicineDong-A PharmaceuticalCompleted